CJC-1295 is a modified type of growth hormone releasing hormone (GHRH) with improved pharmacokinetics compared to GHRH. There is some limited evidence that it increases growth hormone and IGF-1 levels, indicating some potential for body composition indications.
GHRH is a 44-amino acid peptide responsible for stimulating secretion of growth hormone (GH). CJC-1295 is a synthetic analog of GHRH. It covalently and selectively binds to endogenous albumin post-injection. In doing so its half-life and duration of action increase (1).
In preclinical studies, CJC-1295 was administered to GHRH knockout mice. Mice received either CJC-1295 or placebo for a period of five weeks, at intervals of either 24, 48, or 72 hours. Mice that received CJC-1295 obtained higher body weights and length versus placebo-treated animals. The findings suggest that once daily treatment with CJC-1295 in mice allowed for maintenance of normal growth and body composition (1).
One study has evaluated the effects of CJC-1295 in humans. The study design included two randomized, double-blind, placebo-controlled ascending dose trials that last 28 and 49 days. Participants included healthy subjects that were between the ages of 21 and 61 years old, and they received single and repeated doses of CJC-1295 over the course of several weeks. The study found that subcutaneous administration of CJC-1295 led to dose-dependent and sustained increases in GH and IGF-I levels. It was also considered to be generally safe and well tolerated at doses of 30 and 60 mcg/kg (2).
The randomized controlled study involving CJC-1295 demonstrated that the peptide has pharmacological activity in humans, making it the strongest evidence available that supports its use. The study’s result of increased growth hormone and IGF-1 levels post-administration indicate that CJC-1295 could be a promising candidate. However, this was an early-phase study and one of the only ones conducted in humans thus far. Additionally, lack of regulatory approval restricts its current use.
From a regulatory perspective, CJC-1295 is not approved by the US Food and Drug Administration (FDA), and thus it has no approved medical indications. While an early phase study of CJC-1295 does exist, the compound did not progress into later phase trials or to receive FDA approval. As such, the long-term benefit-risk profile remains unclear.
Additionally, CJC-1295 is not on the FDA-approved bulk substance list, and thus is not eligible to be compounded. Any CJC-1295 that is available carries many of the risks associated with unapproved peptide therapy, including potential quality concerns (e.g., mislabeling, purity, etc.).
Studies show that CJC-1295 activates the GH and IGF-1 axis, which demonstrates its ability to increase GH and IGF-1 signaling. While this could be beneficial therapeutically, there are some theoretical risks associated with this mechanism, such as metabolic effects and tumor growth (3).
There is some limited evidence that support CJC-1295’s mechanism in modulating the GH/IGF-1 axis. However, it’s risk-benefit profile is still unclear at this stage, which is why it is not approved by the FDA.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available.
If you’re interested in how peptides like CJC-1295 may influence growth hormone and recovery, it’s important to understand how these therapies fit into a medically supervised, evidence-based approach—learn more about our Growth Hormone Peptides program and how we evaluate safe, appropriate options for patients here: Medically Supervised Growth Hormone Peptide Therapy
References
